Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1400 - Proof-of-concept of a risk calculator of chemotherapy induced (febrile) neutropenia (CIN/FN) based on real-world evidence (Monitor-GCSF study) (522P)

Date

18 Nov 2017

Session

Poster lunch

Presenters

Carsten Bokemeyer

Citation

Annals of Oncology (2017) 28 (suppl_10): x155-x165. 10.1093/annonc/mdx676

Authors

C. Bokemeyer1, M. Aapro2, H. Ludwig3, P. Gascón4, M. Boccadoro5, K. Denhaerynck6, A. Krendyukov7, K. Macdonald6, I. Abraham6

Author affiliations

  • 1 Oncology, University of Hamburg-Eppendorf, 20246 - Hamburg/DE
  • 2 Multidisciplinary Oncology Institute, Genolier Cancer Center, Genolier/CH
  • 3 Internal Medicine, Wilhelminen Cancer Research Institute, Vienna/AT
  • 4 Medical Oncology, Hospital Clínic de Barcelona, Barcelona/ES
  • 5 Hematology, S. Giovanni Battista University Hospital of Turin, Turin/IT
  • 6 Matrix45, Matrix45, Tucson/US
  • 7 Hexal Ag, Hexal AG, Holzkirchen/DE
More

Resources

Abstract 1400

Background

Predictive modeling of CIN/FN prophylaxis with Zarzio®, a biosimilar filgrastim, in the pan-European MONITOR-GCSF study identified several risk factors at the patient level (“ever” during chemotherapy) and cycle level (during cycle) of 5 outcomes: CIN grade 4, FN, CIN/FN-related hospitalizations or chemotherapy disturbances, and “worst case” composite (Aapro et al, Ann Oncol 2016). We used these modeling results as proof-of-concept data for the development of a calculator of patient and cycle level risk for these outcomes.

Methods

Using the 2016 modeling generated odds ratios (OR), we specified an analytics algorithm to calculate probabilities for best to worst scenarios by 1) taking the OR natural logarithm, 2) applying log odds to the predictors, 3) summing intercept and log odds to obtain total log odds, 4) then converted to total OR, 5) to compute outcome probability, and 6) to estimate best to worst scenarios. Best scenario assumed absence of all negative and presence of all positive predictors; and vice versa for worst scenario.

Results

Patient level: risk of “ever” experiencing any of 5 outcomes ranged from

Conclusions

This analysis based on the proof-of-concept data have yielded an intriguing model. The statistical analytics and the results thus generated show the feasibility of estimating the risk of CIN/FN episodes, CIN/FN-related hospitalizations and chemotherapy disturbances at the start (“ever”) of a line of chemotherapy, and at start of each cycle. These risk calculations are based on real-world evidence, enhancing external validity, and conform to recent ESMO guidelines for G-CSF usage (Klastersky et al, Ann Oncol 2016), assuring internal validity. A risk calculator for use in daily clinical practice is being developed and will be submitted to validation studies.

Clinical trial identification

N/A

Legal entity responsible for the study

Sandoz Biopharmaceuticals

Funding

Sandoz Biopharmaceuticals

Disclosure

C. Bokemeyer: Hexal AG (personal fees). M. Aapro: Amgen (honoraria, speakers bureau, expert testimony), Helsinn Healthcare (advisory role, speakers bureau, research funding), Hospira (advisory role, speakers bureau, research funding), Teva (advisory role, speakers bureau), Merck KGaA (advisory role), Merck (advisory role), Sandoz (advisory role, speakers bureau, research funding), Pierre Fabre Medicament (advisory role, speakers bureau, research funding), Vifor Pharma (advisory role, speakers bureau), Tesaro (advisory role, speakers bureau), Novartis (speakers bureau, research funding), Roche (speakers bureau), Johnson & Johnson (speakers bureau). H. Ludwig: Celgene (speaker’s honoraria), Takeda (research funding, speaker’s honoraria), Amgen (honoraria for advisory boards and speakers board). P. Gascón: Sandoz (speakers bureau). M. Boccadoro: Celgene (personal fees), Novartis (personal fees), Amgen (personal fees), Sanofi (personal fees). K. Denhaerynck: Matrix45 (employment). Matrix45 has been under contract for scientific consulting services to GCSF manufacturers including Hospira, Hexal/Sandoz and Therapeutic Proteins International. By company policy, employees cannot hold equity in sponsor organizations and cannot receive direct personal benefits, financial or other, from sponsor organizations. A. Krendyukov: Hexal AG (employment). K. Macdonald, I. Abraham: Matrix45 (employment). Matrix45 is under contract with study Sponsor, Hexal/Sandoz, for scientific support services including study design, statistical analysis and manuscript preparation for the MONITOR-GCSF study. Matrix45 has been under contract for scientific consulting services to other GCSF manufacturers including Hospira. By company policy, employees cannot hold equity in sponsor organizations and cannot receive direct personal benefits, financial or other, from sponsor organizations. Matrix45 provides similar services to other biopharmaceutical companies without exclusivity constraints.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.